Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients

Phase 1 Completed 17 enrolled Tanabe Pharma Corporation

Non-randomizedParallel-groupOpen-labelTreatment

The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosus

Evaluation	Drug	Modality	Dose	Route
Subject	amiselimod	Small molecule	0.2 mg	Oral
Subject	amiselimod	Small molecule	0.4 mg	Oral